SEC Tracker
Get the app
PLRX · XBRL financial data

Pliant Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PLRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*0000*———year only——
Research and development32,33933,183*37,14645,61747,75438,793*43,43632,19817,93815,585*13,58416,727
General and administrative15,34613,854*15,24615,02214,26014,527*15,49913,39410,3317,992*8,1887,135
Total operating expenses47,68547,037*52,39260,63962,01453,320*58,93545,59228,26923,577*21,77223,862
Operating income (loss)(47,685)(47,037)*(52,392)(60,639)(62,014)(53,320)*(58,935)(45,592)(28,269)(23,577)*(21,772)(23,862)
Interest expense317321*445868877834*799809815136*00
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(41,487)(41,109)*(46,955)(55,854)(57,763)(49,732)*(56,166)(43,300)(26,301)(23,577)*(20,040)(22,371)
Earnings per share, basic USD per share(0.70)(0.69)*(0.78)(0.92)(0.95)(0.82)*(0.92)(0.71)(0.43)(0.38)*(0.32)(0.36)
Earnings per share, diluted USD per share(0.70)(0.69)*(0.78)(0.92)(0.95)(0.82)*(0.92)(0.71)(0.43)(0.38)*(0.32)(0.36)
Weighted average shares, basic thousands of shares59,68859,904*60,18160,38360,73160,854*61,22361,38661,40661,449*61,80361,919
Weighted average shares, diluted thousands of shares59,68859,904*60,18160,38360,73160,854*61,22361,38661,40661,449*61,80361,919

Balance sheet

CSV

Fiscal quarters (PLRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents57,67963,234114,29780,38679,61671,18891,93686,82093,73245,44522,19024,883
Short-term investments465,933431,011368,092356,221324,897284,536213,709176,053148,065145,499148,702133,218
Accounts receivable00——————————
Prepaid and other current assets10,64011,2577,50910,9465,5186,5405,5464,5713,7914,4643,1324,135
Total current assets534,335505,502489,898447,553410,031362,264311,191267,444245,588196,448174,930163,142
Property and equipment, net3,9693,5675,6055,3955,6715,5255,2404,8924,3442,9402,6642,414
Right-of-use asset1,7681,21124,22828,86328,05427,24326,43025,61524,79423,96623,13122,289
Total assets540,464512,154521,605483,730445,665396,949344,770299,824276,600225,228202,596189,881
Accounts payable3,3604,5317,3273,2476,8905,9605,6221,3844854803621,531
Accrued liabilities8,31010,2195,8688,1969,71512,3537,4297,1928,1739,6344,1433,653
Total current liabilities27,39528,52430,39130,92439,95233,21828,20320,59117,62416,36510,35916,484
Lease liability, non-current0023,88030,05829,75229,43929,11928,79128,23127,65827,07126,471
Total liabilities37,41638,57884,27391,05299,84392,86887,60679,74276,29444,02337,43042,955
Accumulated deficit(458,639)(499,748)(546,703)(602,557)(660,320)(710,052)(766,218)(809,518)(835,819)(859,396)(879,436)(901,807)
Total stockholders' equity503,048473,576437,332392,678345,822304,081257,164220,082200,306181,205165,166146,926
Total liabilities and equity540,464512,154521,605483,730445,665396,949344,770299,824276,600225,228202,596189,881
Common shares outstanding (cover page) thousands of shares59,89660,23960,32660,80160,85461,23661,38661,38861,44961,91561,92061,922

Cash flows

CSV

Fiscal quarters (PLRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(41,487)(41,109)*(46,955)(55,854)(57,763)(49,732)*(56,166)(43,300)(26,301)(23,577)*(20,040)(22,371)
Stock-based compensation10,362*9,152*9,66610,644*8,899*8,417*8,9136,378*6,418*4,525*4,2544,187*
Net cash from operating activities(36,224)*(25,102)*(30,271)(45,297)*(32,273)*(47,662)*(48,864)(40,603)*(21,081)*(17,788)*(19,229)(12,797)*
Purchases of property and equipment94*61*1,4921,251*896*209*262112*0*0*00*
Net cash from investing activities38,253*31,921*59,54610,702*30,960*39,132*69,11435,487*27,921*1,768*(4,100)15,490*
Net cash from financing activities699*219*21,788684*543*102*4980*72*(32,267)*740*
Net change in cash2,728*7,038*51,063(33,911)*(770)*(8,428)*20,748(5,116)*6,912*(48,287)*(23,255)2,693*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Pliant Therapeutics24,883not reported(12,797)*61.9M12.4 quarters 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings23,370not reported(29,626)*19.3M4.0 quarters 10-QJun 30, 2026
Seres Therapeutics17,528593(10,477)*10.2M1.1 quarters 10-QSep 30, 2026
Oncolytics Biotech4,115not reported(8,138)*127.5M0.5 quarters 10-QJun 30, 2026
Gyre Therapeutics43,28729,105(16,728)*111.5M3.4 quarters 10-QJun 30, 2026
Volitionrx2,800399(5,160)*13.6M0.5 quarters 10-QJun 30, 2026
Macrogenics113,90732,832(40,748)*63.7M2.8 quarters 10-QJun 30, 2026
Inovio Pharmaceuticals31,5260(18,047)*103.4M2.0 quarters 10-QJun 30, 2026
Whitehawk Therapeutics85,2340(14,529)*57.0M13.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.